查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968412

癌症生物疗法市场－全球产业规模、份额、趋势、机会、预测：按产品、通路、地区和竞争格局划分，2021-2031年

Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球癌症生物疗法市场预计将从 2025 年的 1,161.2 亿美元成长到 2031 年的 1,820.3 亿美元，复合年增长率达到 7.78%。

癌症生物疗法是指利用活体生物、其衍生物或实验室设计的生物製剂来刺激免疫系统识别并摧毁癌细胞的特殊治疗方法。推动这一市场发展的关键因素包括全球癌症发病率的上升以及临床治疗向精准医疗的转变，精准医疗优先采用标靶生物干预而非传统的特异性疗法。美国癌症协会预测，到2024年，美国将新增2,001,140例癌症病例，这意味着需要有效治疗方案的患者群体将显着扩大。

市场概览
预测期 2027-2031
市场规模：2025年 1161.2亿美元
市场规模：2031年 1820.3亿美元
复合年增长率：2026-2031年 7.78%
成长最快的细分市场 单株抗体
最大的市场 北美洲

儘管市场需求强劲，但由于研发和生产这些复杂生物製药的成本极为高昂，市场面临许多障碍。这些经济障碍导致治疗价格高昂，对医疗预算造成压力，并限制了病患的就医机会，尤其是在健保报销机制有限的发展中地区。

市场驱动因素

新型生物製药的快速监管审批途径从根本上改变了全球癌症生物治疗市场，缩短了从临床检验到患者用药的时间。监管机构正在扩大快速审批流程的应用范围，以加速创新治疗方法（尤其是针对罕见疾病和难治性癌症的疗法）的上市。这种精简的环境不仅促进了药物创新，也确保了治疗方案的快速扩展。例如，美国癌症研究协会（AACR）在其2024年1月出版的《癌症研究催化剂》（Cancer Research Catalyst）杂誌中指出，美国食品药物管理局（FDA）在2023年核准了45种抗癌药物，显示这些复杂治疗方法的上市核准势头持续强劲。

同时，靶向单株抗体的日益普及仍然是市场收入和临床实践的主要驱动力。这些生物製药已成为多种固态肿瘤的标准治疗方案，凭藉其在一线治疗和辅助性治疗中的高使用率，推动了显着的商业性成长。关键查核点抑制剂的优异表现反映了该领域的经济规模。根据默克公司于2024年2月发布的《2023年第四季及全年财务业绩报告》，Keytruda的年销售额在2023年成长了19%，达到250亿美元。这项商业性成功得益于公司在创新方面的大量资本投入。根据百时美施贵宝公司于2024年3月发布的《2023财年年度报告》，该公司宣布投资93亿美元用于研发，以推动其产品系列的发展。

市场挑战

复杂生物製药的研发和生产高成本，是全球癌症生物疗法市场成长的主要障碍。不断飙升的生产成本迫使製药公司采取高价策略以收回研发投资，最终加重了全球医疗预算和保险体系的负担。因此，已开发国家和开发中国家的支付方都在实施更严格的报销标准，并越来越多地延迟或拒绝支付这些先进疗法的费用。这种财务摩擦限制了能够接受治疗的患者群体，并阻碍了临床有效治疗方法的市场渗透。

根据美国癌症协会预测，到2025年，许多新型抗癌药物的年度定价将超过10万美元，给病患和医疗系统带来沉重的经济负担。这种定价结构导致患者因经济压力过大而放弃治疗的比例居高不下，直接阻碍了市场成长。临床需求与经济可行性之间的差距降低了生物疗法的商业性应用，也阻碍了市场充分发挥其获利潜力。

市场趋势

癌症生物相似药的迅速普及，透过提供价格低廉的替代疗法，从根本上改变了市场结构，取代了价格昂贵的原厂生物製药。这一趋势的主要驱动因素是重磅药物专利到期，以及在不影响临床疗效的前提下优化医疗成本的迫切需求。生物相似药以更低的价格提供临床疗效相当的治疗方案，扩大了患者获得必要生物疗法的机会，尤其是在资源匮乏的环境中。这种经济转变至关重要。根据美国可及药品协会（Association for Accessible Medicines）于2025年9月发布的《2025年美国非专利和生物类似药节省报告》，自生物类似药上市以来，该行业已累计为患者和医疗系统节省了562亿美元。

同时，抗体药物复合体（ADC）的研发正蓬勃发展，为标靶癌症治疗树立了新的典范。製药公司正大力投资于这项疗法，该疗法结合了单株抗体的特异性和细胞毒性药物的疗效，能够将药物直接递送至癌细胞，同时最大限度地减少目标外毒性。这种趋势推动了已通过核准的ADC的快速商业性成长，展现了其在多种适应症中取代传统化疗的潜力。根据辉瑞公司于2025年8月发布的2025年第二季财报，其抗体药物复合体Padsev的全球销售额达到5.42亿美元，年增38%，反映了市场对这种精准药物的高临床需求和市场渗透率。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球癌症生物疗法市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依产品类型（癌症生长抑制剂、单株抗体、疫苗）
    • 通路（医院、零售/邮购药局）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美癌症生物疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲癌症生物疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区癌症生物疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲癌症生物疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲癌症生物疗法市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球癌症生物疗法市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • F Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck KgAa
  • Amgen Inc
  • GSK PLC
  • Celgene Corp
  • Pfizer Inc
  • Zydus Lifesciences Ltd
  • Sun Pharmaceutical Industries Ltd
  • Bayer AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 18861

The Global Cancer Biological Therapy Market is projected to expand from USD 116.12 Billion in 2025 to USD 182.03 Billion by 2031, achieving a compound annual growth rate of 7.78%. Cancer biological therapy refers to a specialized class of treatments that utilize living organisms, their derivatives, or laboratory-engineered versions to prompt the immune system to identify and destroy malignant cells. The primary forces driving this market include the rising global incidence of cancer and a clinical shift toward precision medicine, which prioritizes targeted biological interventions over traditional non-specific treatments. As reported by the American Cancer Society, the United States was expected to see 2,001,140 new cancer cases in 2024, highlighting the substantial and expanding patient population in need of effective therapeutic options.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 116.12 Billion
Market Size 2031USD 182.03 Billion
CAGR 2026-20317.78%
Fastest Growing SegmentMonoclonal Antibodies
Largest MarketNorth America

Despite robust demand, the market faces significant hurdles due to the prohibitive costs associated with developing and manufacturing these complex biologics. This financial barrier leads to high treatment prices that strain healthcare budgets and restrict patient access, particularly in developing regions with limited reimbursement frameworks.

Market Driver

Accelerated regulatory pathways for new biologics have fundamentally transformed the Global Cancer Biological Therapy Market by shortening the timeline between clinical validation and patient availability. Regulatory agencies have increasingly adopted expedited review processes to speed up the entry of innovative therapies, particularly for rare and refractory cancers. This streamlined environment not only encourages pharmaceutical innovation but also ensures the rapid broadening of treatment options. For instance, the American Association for Cancer Research noted in its January 2024 'Cancer Research Catalyst' that the U.S. Food and Drug Administration approved 45 oncology drugs in 2023, demonstrating the continued momentum of market authorizations for these complex interventions.

Concurrently, the growing adoption of targeted monoclonal antibodies remains a primary driver of market revenue and clinical practice. These biologic agents have become the standard of care for numerous solid tumors, driving significant commercial growth through high utilization in both first-line and adjuvant settings. The financial scale of this segment is illustrated by the performance of leading checkpoint inhibitors; according to Merck & Co.'s 'Fourth-Quarter and Full-Year 2023 Financial Results' released in February 2024, annual sales of Keytruda rose 19% to $25.0 billion in 2023. This commercial success is supported by massive capital investment in innovation, as evidenced by Bristol Myers Squibb's '2023 Annual Report' from March 2024, which reported a $9.3 billion investment in research and development to advance its portfolio.

Market Challenge

The high costs associated with the development and manufacturing of complex biologics represent a major obstacle to the growth of the Global Cancer Biological Therapy Market. These elevated production expenses force pharmaceutical companies to adopt premium pricing strategies to recoup their research and development investments, thereby straining healthcare budgets and insurance systems worldwide. Consequently, payers in both developed and developing regions are enforcing stricter reimbursement criteria, often delaying or denying coverage for these advanced treatments. This financial friction limits the accessible patient population and impedes the market penetration of otherwise clinically effective therapies.

According to the American Cancer Society, in 2025, the annual list price for many new cancer prescription medicines exceeded $100,000, creating a severe financial burden for patients and healthcare systems. This pricing structure directly hampers market growth by fueling high rates of financial toxicity, which frequently compels patients to forgo or discontinue necessary treatment. The resulting gap between clinical necessity and economic feasibility reduces the commercial adoption of biological therapies, preventing the market from realizing its full revenue potential.

Market Trends

The rapid adoption of oncology biosimilars is fundamentally restructuring the market by introducing cost-effective alternatives to expensive reference biologics. This trend is primarily driven by the patent expiration of major blockbuster drugs and the intensified need for healthcare systems to optimize spending without compromising clinical outcomes. By offering clinically equivalent therapeutic options at reduced prices, biosimilars are expanding patient access to essential biological treatments, particularly in resource-constrained settings. This economic shift is significant; according to the Association for Accessible Medicines' '2025 U.S. Generic & Biosimilar Medicines Savings Report' from September 2025, the biosimilars industry has generated $56.2 billion in cumulative savings for patients and the healthcare system since these agents first entered the market.

At the same time, a surge in the development of antibody-drug conjugates (ADCs) is establishing a new paradigm in targeted cancer intervention. Pharmaceutical companies are heavily investing in this modality, which combines the specificity of monoclonal antibodies with the potency of cytotoxic agents to deliver payloads directly to tumor cells while minimizing off-target toxicity. This focus has translated into rapid commercial growth for approved ADCs, validating their potential to replace conventional chemotherapy in multiple indications. According to Pfizer Inc.'s 'Second-Quarter 2025 Earnings' report from August 2025, global sales of the antibody-drug conjugate Padcev increased 38% year-over-year to reach $542 million, underscoring the high clinical demand and market uptake for these precision therapeutics.

Key Market Players

  • F Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck KgAa
  • Amgen Inc
  • GSK PLC
  • Celgene Corp
  • Pfizer Inc
  • Zydus Lifesciences Ltd
  • Sun Pharmaceutical Industries Ltd
  • Bayer AG

Report Scope

In this report, the Global Cancer Biological Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Biological Therapy Market, By Product

  • Cancer Growth Blockers
  • Monoclonal Antibodies
  • Vaccines

Cancer Biological Therapy Market, By Distribution Channel

  • Hospitals
  • Retail & Mail Order Pharmacies

Cancer Biological Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Biological Therapy Market.

Available Customizations:

Global Cancer Biological Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Biological Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Cancer Growth Blockers, Monoclonal Antibodies, Vaccines)
    • 5.2.2. By Distribution Channel (Hospitals, Retail & Mail Order Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cancer Biological Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cancer Biological Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Cancer Biological Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Cancer Biological Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Distribution Channel

7. Europe Cancer Biological Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cancer Biological Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Cancer Biological Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Cancer Biological Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Cancer Biological Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Cancer Biological Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Cancer Biological Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cancer Biological Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Cancer Biological Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Cancer Biological Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Cancer Biological Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Cancer Biological Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Cancer Biological Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cancer Biological Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Cancer Biological Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Cancer Biological Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Distribution Channel

10. South America Cancer Biological Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Biological Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Cancer Biological Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Cancer Biological Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cancer Biological Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Merck KgAa
  • 15.4. Amgen Inc
  • 15.5. GSK PLC
  • 15.6. Celgene Corp
  • 15.7. Pfizer Inc
  • 15.8. Zydus Lifesciences Ltd
  • 15.9. Sun Pharmaceutical Industries Ltd
  • 15.10. Bayer AG

16. Strategic Recommendations

17. About Us & Disclaimer